-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Kymera Therapeutics, Raises Price Target to $128

Benzinga·03/03/2026 19:14:59
Listen to the news
UBS analyst David Dai maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $90 to $128.